Amarin reported $602.76M in Current Assets for its fiscal quarter ending in June of 2026.





Current Assets Change Date
AbbVie USD 33.67B 140M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amarin USD 602.76M 23.26M Jun/2026
AstraZeneca USD 27.97B 1.65B Jun/2026
BioCryst Pharmaceuticals USD 484.68M 111.06M Jun/2026
DBV Technologies USD 201.9M 44.8M Jun/2026
GlaxoSmithKline GBP 17.56B 202M Jun/2026
Halozyme Therapeutics USD 1B 177.83M Mar/2026
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 1.64B 798.6M Jun/2026
Novartis USD 27.35B 744M Jun/2026